Glucagon-Like Peptide 1 Receptor Agonists and Mental Health

作者：Aureliane C. S. Pierret, Yuya Mizuno, Pippa Saunders, Eshaya Lim, Riccardo De Giorgi, Oliver Howes, Robert A. McCutcheon, Barbara McGowan, Piya Sen Gupta, Daniel J. Smıth, Khalida Ismail, Toby Pillinger · 发表于：JAMA Psychiatry · 年份：2025 · DOI：10.1001/jamapsychiatry.2025.0679 · 被引用次数：86 · 研究领域：Diabetes Treatment and Management、Diabetes Management and Research、Bariatric Surgery and Outcomes

Importance: People with obesity and diabetes have poorer psychiatric and cognitive outcomes and lower quality of life (QOL) compared with those without. Glucagon-like peptide 1 receptor agonists (GLP1-RAs) are treatments for diabetes and obesity that may also influence psychiatric outcomes. Objective: To conduct a meta-analysis of randomized placebo-controlled trials to evaluate psychiatric, cognitive, and QOL outcomes with GLP1-RA treatment. Data Sources: MEDLINE, Embase, PsycINFO, and CENTRAL databases were searched from inception through June 24, 2024. Study Selection: Double-blind placebo-controlled trials comparing GLP1-RA to placebo in adults with overweight/obesity and/or diabetes, reporting on psychiatric, cognition, or QOL outcomes, were included. Data Extraction and Synthesis: Data extraction was performed in parallel by 2 reviewers. Random-effects meta-analysis was performed. Effect size measures were log risk ratios (log[RR]) and standardized mean differences (Hedges g). The quality of studies was appraised using the Cochrane risk-of-bias tool (RoB2). Certainty of evidence was assessed via GRADEpro. Main Outcomes and Measures: Main outcomes were risk of psychiatric adverse events (serious and nonserious) and change in mental health symptom severity, health-related quality of life, and cognition. Results: Eighty randomized clinical trials involving 107 860 patients were included in the meta-analysis. The mean (SD) age of participants across studies in the meta-anal...